All In MedTech

FDA Clearance Tracker · P240035

ETHIZIA

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Dec 15, 2025

Approved

Time to decision

424 days

Received Oct 17, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240035
Device name
ETHIZIA
Applicant
ETHICON, Inc.
Applicant location
Raritan, NJ
Received
Oct 17, 2024
Decided
Dec 15, 2025
Decision
Approved
Supplements
6 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code SGV

FDA's approval statement

As written in FDA's record.

Approval for ETHIZIA™ indicated for use in adult patients with a body weight of greater than or equal to 25kg as an adjunct to hemostasis in open liver surgery for minimal, mild, or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SGV (Agent, absorbable hemostatic, collagen with polymeric additives).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for ETHICON, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.